Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000817435 | SCV000957995 | pathogenic | not provided | 2024-12-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg727*) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653, 37402566). This variant is present in population databases (rs376667075, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. ClinVar contains an entry for this variant (Variation ID: 660274). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002427027 | SCV002727300 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-12-19 | criteria provided, single submitter | clinical testing | The p.R727* pathogenic mutation (also known as c.2179C>T), located in coding exon 15 of the MSH3 gene, results from a C to T substitution at nucleotide position 2179. This changes the amino acid from an arginine to a stop codon within coding exon 15. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003458547 | SCV004189073 | pathogenic | Familial adenomatous polyposis 4 | 2023-08-30 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Baylor Genetics | RCV003461246 | SCV004197504 | likely pathogenic | Endometrial carcinoma | 2022-08-25 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000817435 | SCV005436381 | pathogenic | not provided | 2024-11-01 | criteria provided, single submitter | clinical testing | MSH3: PVS1, PM2 |